Health Canada Approves LEQEMBI for Early Alzheimer's Treatment
Eisai Co., Ltd. and Biogen Inc. announced that Health Canada has granted authorization for LEQEMBI (lecanemab) for treating early Alzheimer's disease.
The approval is for adult patients with mild cognitive impairment or mild dementia due to Alzheimer's disease, who are apolipoprotein E ε4 non-carriers or heterozygotes with confirmed amyloid pathology.
LEQEMBI is the first treatment for early AD that targets an underlying cause of the disease, to be authorized in Canada.
Author's summary: LEQEMBI approved for early Alzheimer's in Canada.
More News
- Flyers send Jett Luchanko back to juniors as development takes priority | NorthPennNow
- Edwards shares superior long-term outcomes from TAVR studies
- Why Every Venue Needs Its Own ‘Black Box’ for Public Safety
- “No Faux King Way”: ‘No Kings’ Protesters Fighting Against Trumpism And White Christian Nationalists - Black Star News
- Man Utd Failed With £50 Million Mbeumo Alternative
- Tonight’s ‘Sports Equinox’ will showcase games throughout the NFL, MLB, NBA and NHL
- Eglin battalion chief and wife lose Crestview home to lightning strike, community rallies in support
- SJHN Daily: Celebrini Named NHL First Star of the Week
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Importing beef is not the solution | GABEL